AZGP1 and prostate adenocarcinoma: Gagnon S et al. also proved that AZGP1 was present in benign hyperplastic glands in 91.1% of cases but in only 40.7% (poorly differentiated component) to 48.5% (well differentiated component) of prostatic adenocarcinomas and only 8% of metastases [27].